Protection efficacy of mRNA-based SARS-CoV-2 variant vaccine in non-human primates.

Acta Pharm Sin B · 2025 · PMC11959875 · PMID 40177573

Europe PMC DOI

hedged sentence

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

almost significantlyP < 0.001actually significant

However, they were almost significantly higher than those against the Delta variant (IFN γ : BA.1, ∼2.99-fold, P < 0.001; XBB.1, ∼3.58-fold, P < 0.001; IL-2: BA.1, ∼1.47-fold, P < 0.01) ( Fig. 6 C and D).

also in 555 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.